Somatic BRCA mutations, occurring in non-germline cells, have garnered significant attention due to their predictive value and therapeutic implications, particularly in the context of cancer management. The discovery of BRCA mutations, initially linked with hereditary breast and ovarian cancers, has now extended to various other cancers, including prostate, pancreatic, and others. Understanding the predictive value of somatic BRCA mutations and their therapeutic significance is crucial for personalized cancer treatment strategies. This article aims to delve into the predictive implications of somatic BRCA mutations and explore the therapeutic avenues they offer in cancer management.
HTML PDFShare this article
Journal of Genetics and DNA Research received 3 citations as per Google Scholar report
